41 related articles for article (PubMed ID: 17655703)
1. Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia.
McMaster ML; Berndt SI; Zhang J; Slager SL; Li SA; Vajdic CM; Smedby KE; Yan H; Birmann BM; Brown EE; Smith A; Kleinstern G; Fansler MM; Mayr C; Zhu B; Chung CC; Park JH; Burdette L; Hicks BD; Hutchinson A; Teras LR; Adami HO; Bracci PM; McKay J; Monnereau A; Link BK; Vermeulen RCH; Ansell SM; Maria A; Diver WR; Melbye M; Ojesina AI; Kraft P; Boffetta P; Clavel J; Giovannucci E; Besson CM; Canzian F; Travis RC; Vineis P; Weiderpass E; Montalvan R; Wang Z; Yeager M; Becker N; Benavente Y; Brennan P; Foretova L; Maynadie M; Nieters A; de Sanjose S; Staines A; Conde L; Riby J; Glimelius B; Hjalgrim H; Pradhan N; Feldman AL; Novak AJ; Lawrence C; Bassig BA; Lan Q; Zheng T; North KE; Tinker LF; Cozen W; Severson RK; Hofmann JN; Zhang Y; Jackson RD; Morton LM; Purdue MP; Chatterjee N; Offit K; Cerhan JR; Chanock SJ; Rothman N; Vijai J; Goldin LR; Skibola CF; Caporaso NE
Nat Commun; 2018 Oct; 9(1):4182. PubMed ID: 30305637
[TBL] [Abstract][Full Text] [Related]
2. Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience.
Danesin N; Bonaldi L; Martines A; Nalio S; Bertorelle R; Compagno S; Marcato R; Manni S; Scarmozzino F; Pizzi M; Tos APD; Cellini A; Scapinello G; Visentin A; Trentin L; Piazza F
Ann Hematol; 2024 Apr; ():. PubMed ID: 38687347
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
Dhodapkar MV; Hoering A; Gertz MA; Rivkin S; Szymonifka J; Crowley J; Barlogie B
Blood; 2009 Jan; 113(4):793-6. PubMed ID: 18931340
[TBL] [Abstract][Full Text] [Related]
4. Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström's Macroglobulinemia-A Particularly Heterogeneous Lymphoma.
García-Sanz R; Jiménez C
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810569
[TBL] [Abstract][Full Text] [Related]
5. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
[TBL] [Abstract][Full Text] [Related]
6. Candidate genes of Waldenström's macroglobulinemia: current evidence and research.
Bianchi G; Sacco A; Kumar S; Rossi G; Ghobrial I; Roccaro A
Appl Clin Genet; 2013; 6():33-42. PubMed ID: 23935380
[TBL] [Abstract][Full Text] [Related]
7. Genetic factors and pathogenesis of Waldenström's macroglobulinemia.
Monge J; Braggio E; Ansell SM
Curr Oncol Rep; 2013 Oct; 15(5):450-6. PubMed ID: 23901022
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of Waldenstrom's macroglobulinemia.
Braggio E; Philipsborn C; Novak A; Hodge L; Ansell S; Fonseca R
Haematologica; 2012 Sep; 97(9):1281-90. PubMed ID: 22773606
[TBL] [Abstract][Full Text] [Related]
9. [Chromosomal abnormalities and Waldenström macroglobulinemia].
Berger R; Nguyen-Khac F
Pathol Biol (Paris); 2008 Sep; 56(6):400-6. PubMed ID: 18456427
[TBL] [Abstract][Full Text] [Related]
10. Waldenström macroglobulinemia with karyotypic aberrations involving both homologous 6q.
Wong KF; So CC
Cancer Genet Cytogenet; 2001 Jan; 124(2):137-9. PubMed ID: 11172905
[TBL] [Abstract][Full Text] [Related]
11. Analysis of 6q deletion in Waldenstrom macroglobulinemia.
Chang H; Qi X; Xu W; Reader JC; Ning Y
Eur J Haematol; 2007 Sep; 79(3):244-7. PubMed ID: 17655703
[TBL] [Abstract][Full Text] [Related]
12. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
Schop RF; Van Wier SA; Xu R; Ghobrial I; Ahmann GJ; Greipp PR; Kyle RA; Dispenzieri A; Lacy MQ; Rajkumar SV; Gertz MA; Fonseca R
Cancer Genet Cytogenet; 2006 Sep; 169(2):150-3. PubMed ID: 16938573
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.
Chang H; Qi C; Trieu Y; Jiang A; Young KH; Chesney A; Jani P; Wang C; Reece D; Chen C
Clin Lymphoma Myeloma; 2009 Mar; 9(1):36-8. PubMed ID: 19362968
[TBL] [Abstract][Full Text] [Related]
14. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.
Ocio EM; Schop RF; Gonzalez B; Van Wier SA; Hernandez-Rivas JM; Gutierrez NC; Garcia-Sanz R; Moro MJ; Aguilera C; Hernandez J; Xu R; Greipp PR; Dispenzieri A; Jalal SM; Lacy MQ; Gonzalez-Paz N; Gertz MA; San Miguel JF; Fonseca R
Br J Haematol; 2007 Jan; 136(1):80-6. PubMed ID: 17222197
[TBL] [Abstract][Full Text] [Related]
15. Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia.
Bang SM; Seo JW; Park KU; Kim SJ; Kim K; Kim SH; Cho SR; Kim HC; Song J; Kim JS; Kim KH; Lee JH; Lee JJ; Shin MG; Suh C; Chi HS; Oh DY; Won JH; Kim HJ; Yoon SS; Lee DS;
Cancer Genet Cytogenet; 2010 Mar; 197(2):117-21. PubMed ID: 20193844
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
